Search

Displaying results 1831 - 1840 of 10000 in total
  1. Drug

    Fludrocortisone

    go.drugbank.com/drugs/DB00687
    ApprovedInvestigational

    of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. … [A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position

  2. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    contribute to the pathophysiology of Alzheimer's Disease (AD). … [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (, Immunoglobulin G1, anti-(human pyroglutamyl Aβ (3-x) peptide)(human clone LY3002813 γ1-chain), disulfide with human clone LY3002813 κ-chain, dimer
  3. Drug

    Hexachlorophene

    go.drugbank.com/drugs/DB00756
    ApprovedWithdrawn

    It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797) … A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms.

    International brands: Pre-Op, Pre-Op II
  4. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822]. … It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns,

  5. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.

    Synonyms: 4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONE
  6. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Paritaprevir as a first line … Paritaprevir first came on the market as a fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak.

    Categories: Antivirals for treatment of HCV infectionsSynonyms: ,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a]
  7. Drug

    Docetaxel

    go.drugbank.com/drugs/DB01248
    ApprovedInvestigational

    Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of [paclitaxel]. … Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: DOCETAXEL DONG-A
  8. Drug

    Idursulfase

    go.drugbank.com/drugs/DB01271
    ApprovedInvestigational

    The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine. … Idursulfase is a 525-amino acid glycoprotein with a molecular weight of approximately 76 kilodaltons.

  9. Drug

    BNT162B2 Omicron (LP.8.1)

    go.drugbank.com/drugs/DB23337
    Approved

    [L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025. … BNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19.

  10. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Regorafenib is an orally-administered inhibitor of multiple kinases. … It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012.

    Categories: UGT1A9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index